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2007 and 2013. Patients with incomplete data and without 
follow up before treatment, were excluded. All patients 
received the same RT scheme: 33 daily fractions of 1.64 Gy 
to intermediate-risk volume and 2.12 Gy to high-risk volume 
with SIB, reaching 54.12 Gy and 69.96 Gy respectively.  
Descriptive statistics (frequencies and percentages) were 
used to report the characteristics of patients, their clinical 
status, the treatment performed and toxicities reported. The 
oncologic outcomes were overall survival (OS), loco-regional 
relapse-free survival (LRRFS), metastases-free survival (MFS) 
and progression free survival (PFS). These variables were 
estimated using the Kaplan-Meier method (95% CI level). 
Results: The median follow-up was 28.1 months. Median age 
was 49 years (range, 15 - 78). There was a predominance of 
men (67.3%), white race (80.8%). The tumors were 
undifferentiated (WHO III) in 40 patients (76.9%), and EBV 
positive in 33 (63.5%). There was a majority of locally 
advanced disease, with 48 patients (92.3%) stage III-IV. Only 5 
patients (9.6%) were treated exclusively with RT, while the 
rest received chemotherapy (CT), mainly concurrent (84.6%). 
Neoadjuvant CT was delivered to 22 (42.3%) patients, 
adjuvant CT to 4 (7.7%) patients and 15 (28.8%) patients 
received neoadjuvant and adjuvant CT. The 1- and 3-year 
estimation of OS was 98.0% and 85.5%, respectively, while 1 
and 3-year LRRFS were 100% and 95.8%, respectively. 
Conclusions: The treatment of NPC (predominantly locally 
advanced) using IMRT-SIB in our institution, offers a rational 
and feasible alternative of treatment, comparable to results 
described so far in endemic population.  
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Purpose/Objective: To analyse the outcome of all the 
patients treated in our Institute for Nasopharyngeal 
Carcinoma without distant metastasis at diagnosis in a period 
of 14 years. 
Materials and Methods: From January 2000 to December 
2013 187 consecutive patients received radiotherapy +/- 
chemotherapy (neoadjuvant and/or concomitant). 
Results: According to TNM classification, UICC 2009, 31% of 
patients were in stage I-II, 69% in stage III-Iva-b. The 
predominant histologic pattern was WHO type 3 in 70.6% of 
patients. At 10 years Overall Survival (OS) has been 65+/-6%, 
Disease Specific Survival (DSS) 82+/-3%, Loco Regional Control 
(LRC) 73+/-5%, Distant Metastasis Free Survival (DMFS) 63+/-
5%. Many clinical variables (gender, histology, age, T and N 
classification, Stage, Karnofski index) and others related to 
treatment (chemotherapy, waiting time from histological 
diagnosis to first treatment, prolongation of overall radiation 
treatment time, technique of treatment - 3DCRT vs IMRT-, 
fractionation), have been analyzed.At univariate analysis OS 
was statistically related to T and N class, clinical stage, 
Karnofski index, concomitant chemotherapy, respect of 
overall treatment time, modality of irradiation. LRC was 
related to T class, clinical stage, chemotherapy, use of IMRT 
and fractionation (2.3 Gy/fr vs 2 Gy/fr). The DMFS resulted 
related to T class, clinical stage, chemotherapy and time 
between the start of neoadjuvant chemotherapy and 
radiotherapy. At multivariate analysis, the statistically 
significant factors at univariate analysis were considered. For 
OS the final model maintained T class, stage, age, and 
chemotherapy. LRC was related with stage, chemotherapy 
and the use of IMRT. DMFS resulted related to the time 
between start of neoadjuvant chemotherapy and the start of 
radiotherapy (worse results for length of time superior to 30 
days). 
Conclusions: In our single experience the introduction of 
IMRT, frequently associated with IGRT, has been associated 
with a sharp improvement of LRC at 5 yrs (88+/-4% with IMRT 
vs 64+/-7% with 3DCRT, p 0.010), even if we consider the 
association with chemotherapy in various modality 
(neoadjuvant chemo followed by RTT alone or RTT/chemo, 
exclusive radio-chemotherapy or radiotherapy alone). Other 
variables could be involved in this improvement, such as a 
better local definition with MR co-registration during 
planning in the last years, or a better staging with the 
frequent use of CT-PET which can identify cases with distant 
metastasis at first diagnosis. 
The gain obtained with IMRT was also evident in an 
improvement in OS (82+/-5% vs 70+/-5% at 5 yrs, p 0.038) 
while no differences were found in DMFS. The analysis is still 
in progress. 
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Purpose/Objective: To investigate the correlation between 
location of loco-regional failures and previous intensity-
modulated radiation therapy (IMRT) target volumes in 
patients with head and neck (H&N) cancer. 
Materials and Methods: 65 consecutive patients (44 men; 
mean age 59.8 years) presenting with biopsy proven failure 
between May 2011 and April 2014 were retrospectively 
reviewed. Primary tumour location was nasopharynx (n = 4), 
oropharynx (n = 23), oral cavity (n = 11), hypopharynx (n = 4), 
larynx (n = 15), salivary gland (n = 1), primary unknown (n= 
1), and sinus (n = 6). Forty-eight patients had primary and 17 
post-operative (chemo)IMRT. Primary radical doses of 65-
70Gy and 54-56 Gy (30-35 fractions) were delivered to high 
dose (PTV1) and prophylactic (PTV2) target volumes, 
respectively, using a SIB-IMRT technique. In the post-
operative setting the dose to PTV1 was 60-66 Gy (30-33 
fractions). The sites of loco-regional failure (persistent or 
recurrent disease) were delineated on the diagnostic FDG-
PET-CT or CT scans which were co-registered with RT 
